Login to Your Account



Other News To Note


Wednesday, June 22, 2011
Amylin Pharmaceuticals Inc., of San Diego, Alkermes Inc., of Waltham, Mass., and Eli Lilly and Co., of Indianapolis, said the European Commission approved Bydureon (exenatide), a once-weekly version of GLP-1 receptor agonist Byetta, for Type II diabetes in adults in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription